--- title: "Rafael-B | 8-K: FY2026 Q3 Revenue: USD 179 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/289460313.md" datetime: "2026-06-11T11:56:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289460313.md) - [en](https://longbridge.com/en/news/289460313.md) - [zh-HK](https://longbridge.com/zh-HK/news/289460313.md) --- # Rafael-B | 8-K: FY2026 Q3 Revenue: USD 179 K Revenue: As of FY2026 Q3, the actual value is USD 179 K. EPS: As of FY2026 Q3, the actual value is USD -0.08. EBIT: As of FY2026 Q3, the actual value is USD -6.59 M. ### Financial Results for the Three Months Ended April 30, 2026 #### Net Loss Rafael Holdings, Inc. reported a net loss attributable to Rafael Holdings, Inc. of - $4.2 million, or - $0.08 per share, for the three months ended April 30, 2026, compared to a net loss of - $4.8 million, or - $0.19 per share, in the prior year period. The year-over-year increase in net loss is primarily due to the consolidation of Cyclo Therapeutic’s expenses following its acquisition in March 2025. #### Revenue Total revenue for the three months ended April 30, 2026, was $179 thousand, down from $362 thousand in the prior year period. Infusion Technology revenue was $0, compared to $42 thousand in the prior year. Rental – Third Party revenue increased to $60 thousand from $49 thousand. Rental – Related Party revenue increased to $30 thousand from $28 thousand. Product revenue decreased to $89 thousand from $243 thousand. #### Operating Expenses Research and development expenses were $4.9 million for the three months ended April 30, 2026, an increase from $3.0 million in the prior year period, primarily due to the inclusion of Cyclo’s R&D spending. General and administrative expenses were $2.1 million, a decrease from $3.2 million in the prior year period, attributed to reductions in payroll, stock-based compensation, and professional fees, partially offset by Cyclo’s expenses. #### Loss from Operations Loss from operations was - $6,870 thousand, compared to - $5,913 thousand in the prior year period. #### Other Income and Expenses Interest income was $286 thousand, down from $472 thousand in the prior year period. Interest expense was - $6 thousand, compared to - $165 thousand in the prior year period. A gain on settlement of accounts payable and convertible notes payable of $3,723 thousand was recorded, compared to $0 in the prior year period. ### Financial Results for the Nine Months Ended April 30, 2026 #### Net Loss For the nine months ended April 30, 2026, Rafael Holdings, Inc. reported a net loss attributable to Rafael Holdings, Inc. of - $20.5 million, or - $0.40 per share, compared to a net loss of - $18.4 million, or - $0.73 per share, in the prior year period. This increase in net loss is primarily due to the consolidation of Cyclo Therapeutic’s expenses following its acquisition in March 2025. #### Revenue Total revenue for the nine months ended April 30, 2026, was $630 thousand, up from $567 thousand in the prior year period. Infusion Technology revenue was $0, compared to $93 thousand in the prior year. Rental – Third Party revenue increased to $173 thousand from $147 thousand. Rental – Related Party revenue increased to $89 thousand from $84 thousand. Product revenue increased to $368 thousand from $243 thousand. #### Operating Expenses Research and development expenses were $16.9 million for the nine months ended April 30, 2026, significantly higher than $5.3 million in the prior year period, due to the inclusion of Cyclo’s spending. General and administrative expenses were $7.3 million, a decrease from $8.3 million in the prior year period, primarily due to reductions in payroll and stock-based compensation, partially offset by Cyclo’s expenses. #### Loss from Operations Loss from operations was - $23,678 thousand, compared to - $16,396 thousand in the prior year period. #### Other Income and Expenses Interest income was $1,023 thousand, down from $1,529 thousand in the prior year period. Interest expense was - $327 thousand, compared to - $490 thousand in the prior year period. A gain on settlement of accounts payable and convertible notes payable of $3,958 thousand was recorded, compared to $0 in the prior year period. ### Balance Sheet Highlights as of April 30, 2026 Cash and cash equivalents were $30.5 million, compared to $52.8 million as of July 31, 2025. Total assets were $91,990 thousand, down from $114,109 thousand as of July 31, 2025. Total liabilities were $11,187 thousand, down from $15,738 thousand as of July 31, 2025. Total equity was $80,803 thousand, down from $98,371 thousand as of July 31, 2025. ### Outlook / Guidance Rafael Holdings, Inc. expects to submit its New Drug Application (NDA) in the second half of calendar year 2026, following a pre-NDA meeting with the FDA. This step is anticipated to provide a clear and expedited path for its lead candidate, Trappsol® Cyclo™, for Niemann-Pick Disease Type C1 (NPC). The company believes this positions Rafael Holdings, Inc. to potentially transition into a commercial-stage biotechnology company. ### Related Stocks - [RFL.US](https://longbridge.com/en/quote/RFL.US.md) ## Related News & Research - [Rafael Holdings expands Alzheimer’s portfolio with MIT license](https://longbridge.com/en/news/283659253.md) - [Rafael Holdings reports Q3 FY2026 net loss of $4.2M; cash $30.5M; NDA expected H2 2026](https://longbridge.com/en/news/289461745.md) - [Rafael Holdings, Inc. 3Q 2026: Revenue $179K, EPS ($0.08) — 10-Q Summary](https://longbridge.com/en/news/289464865.md) - [Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results | RFL Stock News](https://longbridge.com/en/news/289458259.md) - [A Deal Between Vw And The Israeli Defense Company Rafael Is Nearing Completion, Wiwo Says](https://longbridge.com/en/news/286252642.md)